Navigation Links
Defect in A20 gene expression causes rheumatoid arthritis
Date:8/16/2011

Researchers from VIB (Flanders Institute for Biotechnology) and Ghent University have shown that a defective gene can contribute to the onset of rheumatoid arthritis, an often-crippling inflammation of the joints that afflicts about 1% of the world's population. Until now, the underlying molecular mechanism of the disease was largely unclear. In the study, published in Nature Genetics, the researchers demonstrate that a cell-specific defect in the expression of the A20 gene (TNFAIP3) can contribute to the development of rheumatoid arthritis in mice, thereby identifying A20 as a possible target for the generation of new drugs.

Rheumatoid arthritis (RA)

RA is a chronic progressive joint disease that starts with the inflammation of the synovial membrane and soft tissues around the joints, but often spreads to cartilage and bones. The disease is very painful for the patient. Although the cause of rheumatoid arthritis remains unknown, autoimmunity plays a crucial role. Currently, the progression of the disease can be slowed down, but RA cannot be cured.

Protein A20

A20 is an intracellular negative regulator of the NF-kB transcription factor, which plays a key role in the generation of the inflammatory response. Excessive activation of NF-kB can lead to a whole range of inflammatory diseases, including arthritis. The research group of Rudi Beyaert investigates the molecular mechanisms that control NF-kB activation and earlier in vitro research already indicated a key role for A20. Moreover, genome-wide association studies in humans recently suggested that defects in A20 could contribute to several autoimmune diseases, including RA.

Mouse Model for RA

VIB researchers led by Geert van Loo and Rudi Beyaert at Ghent University have developed mice with myeloid cells incapable of producing A20. In collaboration with Dirk Elewaut, rheumatologist at Ghent University Hospital (Ghent University), who co-supervi
'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology technology :

1. Cardica Receives $1 Million Milestone Payment From Cook Medical for Development of Heart Defect Closure Device
2. Worlds First Low Radiocarbon Food May Reduce Risks of Cancer and Birth Defects, and Possibly Even Slow the Aging Process
3. Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences
4. Watching crystals grow provides clues to making smoother, defect-free thin films
5. Nanotube defects equal better energy and storage systems
6. Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreichs Ataxia
7. Supreme Court Amicus Brief Filed Opposing Lawsuit Protection for Manufacturers of Defectively Designed Vaccines
8. Graphenes strength lies in its defects
9. Model Predicts a Drugs Likelihood of Causing Birth Defects
10. Defect in graphene may present bouquet of possibilities
11. Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
(Date:6/18/2013)... , June 18, 2013 ... investment research firm, announces the initiation of ... French biopharmaceutical company developing and marketing products ... indications.      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... report examining the investment merits of BioAlliance ...
(Date:6/18/2013)... June 18, 2013 Mapi Pharma Ltd. ... and innovative intermediates, and finished dosage forms based on selected ... granted a United States patent for ... Europe for the oral treatment of moderate-to-severe acute ... Intermediate Compounds and Processes for the Preparation of Tapentadol ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing ) has announced the addition of ... Markets and Companies " to their offering. ... This report briefly reviews basics of human ... their applications. Current large and small sequencers ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Conference Call at 12:30 p.m. Eastern Time, September 19, ... ... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that Allergan, Inc.,(NYSE: ... States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with,Allergan,s acquisition of ...
... announced that it has filed a registration statement on Form,S-1 ... proposed,initial public offering of its common stock. All of ... The,number of shares to be offered and the price range ... to apply to have its common stock,approved for quotation on ...
... 19 ,Arpida Ltd (SWX: ARPN) was invited to ... new antimicrobial agents at the 47th annual,Interscience Conference ... is a major scientific conference where thousands of,scientists ... to discuss the,latest developments in the field of ...
Cached Biology Technology:Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:6/18/2013)... has awarded $12.7 million to match nine academic ... compounds to explore new treatments for patients in ... dystrophy and schizophrenia. The collaborative pilot initiative, called ... led by the National Center for Advancing Translational ... Fund. , The process of developing a new ...
(Date:6/18/2013)... of breast and ovarian cancers are familial in origin, ... to inherited mutations from the parents in genes such ... PARP inhibitors, which are currently in clinical trials, have ... for personalised cancer treatment, an alternative to standard chemotherapy. ... these patients generate resistance to the drug and, therefore, ...
(Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... 15, 2011 BGI, the world,s largest genomics organization, ... Oregon State University to conduct collaborative de novo genome ... plant pathogens. This agreement kicks off a larger ... Genus Sequencing Consortium, to conduct collaborative de novo genome ...
... even in the cloudiest conditions, while the lush interiors ... canopy. The ability of trees to adapt to light ... photosynthesis in poor light, has been explored by Czech ... Functional Ecology . The research centers around the ...
... In a review study, researchers from Tufts University ... use of antibiotics in food animals and fish farming ... the preponderance of evidence argues for stricter regulation of ... resistance, notes that a guiding tenet of public health, ...
Cached Biology News:BGI announces collaborative research agreements with Oregon State University 2Trees adapt to poor levels of sunlight to effectively process carbon, study shows 2Evidence supports ban on growth promotion use of antibiotics in farming 2Evidence supports ban on growth promotion use of antibiotics in farming 3Evidence supports ban on growth promotion use of antibiotics in farming 4
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
IHC detection kit for BrdU in cells and tissues...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Biology Products: